Is Factor V Leiden Putting You at Risk?

Published: Aug 18, 2024

Factor V Leiden is a genetic mutation that increases your risk of blood clots. Understanding this condition can help manage and reduce potential health risks.

Understanding Factor V Leiden

Factor V Leiden is a mutation in the F5 gene, affecting a protein crucial for blood clotting. This mutation makes the protein resistant to regulation by activated protein C (aPC), a natural anticoagulant. As a result, individuals with this mutation have a higher risk of developing venous thromboembolism (VTE), though many never experience symptoms.

The Risk Factors and Genetics

While Factor V Leiden is the most common inherited thrombophilia in white populations, only a small percentage will develop VTE. The risk increases with other genetic factors like homozygosity or additional mutations. Environmental factors, such as age and hormonal changes, can also heighten the risk.

Factor V Leiden is a genetic mutation in the F5 gene that affects blood clotting, increasing the risk of venous thromboembolism (VTE).

Diagnosis and Testing

Diagnosis of Factor V Leiden involves genetic testing or functional assays for aPC resistance. Genetic testing is more definitive, especially for those with a family history of thrombophilia. Functional assays can be affected by other medications, making genetic testing preferable in some cases.

Frequently Asked Questions

It's a genetic mutation that affects blood clotting and increases clot risk.

It's the most common inherited thrombophilia in white populations.

No, many people with the mutation never develop clots.

Genetic tests and functional assays for aPC resistance.

Key Takeaways

Factor V Leiden is a common mutation, but understanding your genetic risk can help manage potential health impacts.

Get started by discussing your genetic risks with Doctronic today!

Related Articles

References

Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in healthy men. N Engl J Med 1995; 332:912.

Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64.

Always discuss health information with your healthcare provider.